CoChat
Sign Up
Cited by 120Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies ResearchStatistical Methods in Clinical Trials

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab

Open access
Lindauer, A, Valiathan, CR, Mehta, K, Sriram, V, de Greef, R, Elassaiss-Schaap, J, de Alwis, DP·2017·CPT: Pharmacometrics & Systems Pharmacology
DOI 10.1002/psp4.12130PMC PMC5270293
Open this paper in CoChat — free accountOpen PDF

Abstract

Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD-1), has a manageable safety profile and robust clinical activity against advanced malignancies. The lowest effective dose for evaluation in further dose-ranging studies was identified by developing a translational model from preclinical mouse experiments. A compartmental pharmacokinetic model was combined with a published physiologically based tissue compartment, linked to receptor occupancy as the driver of observed tumor growth inhibition. Human simulations were performed using clinical pharmacokinetic data, literature values, and in vitro parameters for drug distribution and binding. Biological and mathematical uncertainties were included in simulations to generate expectations for dose response. The results demonstrated a minimal increase in efficacy for doses higher than 2 mg/kg. The findings of the translational model were successfully applied to select 2 mg/kg as the lowest dose for dose-ranging evaluations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/psp4.12130

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PK/PD model. Parameters are described in Table 1. State variables are abbreviated as follows: C1 = pembrolizumab concentration in the central compartment; C2 = pembrolizumab concentration in the peripheral compartment; PD‐1_b = pembrolizumab: PD‐1 complex; C_PD‐1_b = total PD‐1 receptor concentration in blood; Cvs = pembrolizumab concentration in the vasculature; Ce_ub = concentration of unbound pembrolizumab in the endosomal space; FcRn = Fc receptor levels; Ce_b = pembrolizumab:PD‐1 complex in the endosomal space; Cis = pembrolizumab concentrations in the interstitial space; C_PD‐1_t = total PD‐1 concentration in the tumor; C_PD‐1_b = total PD‐1 concentration in blood; PD‐1_t = pembrolizumab:PD‐1 complex in the tumor; PD‐1_b = pembrolizumab:PD‐1 complex in blood; M_PD‐1_t = amount of PD‐1 receptors in the tumor; Vmax = maximum elimination rate of the saturable pathway; V1 = volume of distribution in the central compartment; V2 = volume of distribution in the central compartment; Km = Michaelis–Menten constant; V_es = endosomal space of the vascular epithelial cells.
Figure 1 PK/PD model. Parameters are described in Table 1. State variables are abbreviated as follows: C1 = pembrolizumab concentration in the central compartment; C2 = pembrolizumab concentration in the peripheral compartment; PD‐1_b = pembrolizumab: PD‐1 complex; C_PD‐1_b = total PD‐1 receptor concentration in blood; Cvs = pembrolizumab concentration in the vasculature; Ce_ub = concentration of unbound pembrolizumab in the endosomal space; FcRn = Fc receptor levels; Ce_b = pembrolizumab:PD‐1 complex in the endosomal space; Cis = pembrolizumab concentrations in the interstitial space; C_PD‐1_t = total PD‐1 concentration in the tumor; C_PD‐1_b = total PD‐1 concentration in blood; PD‐1_t = pembrolizumab:PD‐1 complex in the tumor; PD‐1_b = pembrolizumab:PD‐1 complex in blood; M_PD‐1_t = amount of PD‐1 receptors in the tumor; Vmax = maximum elimination rate of the saturable pathway; V1 = volume of distribution in the central compartment; V2 = volume of distribution in the central compartment; Km = Michaelis–Menten constant; V_es = endosomal space of the vascular epithelial cells.CC BY-NC-ND · PubMed Central
Figure 2 (a) Visual predictive check of tumor volume. Black circles: observations; black line: median of observations; gray area: 90% confidence interval of the median prediction. (b) Receptor occupancy (RO) in tumor vs. plasma concentration of DX400 plotted on a logarithmic scale. Symbols: observations; black line connects median of observations in each bin; shaded gray area: 90% confidence interval around the median prediction.
Figure 2 (a) Visual predictive check of tumor volume. Black circles: observations; black line: median of observations; gray area: 90% confidence interval of the median prediction. (b) Receptor occupancy (RO) in tumor vs. plasma concentration of DX400 plotted on a logarithmic scale. Symbols: observations; black line connects median of observations in each bin; shaded gray area: 90% confidence interval around the median prediction.CC BY-NC-ND · PubMed Central
Figure 3 (a) Simulated tumor response in melanoma (percentage change from baseline diameter) following treatment with pembrolizumab (once every 3 weeks) over 6 months for the six scenarios for melanoma using the fast, medium (MED), and slow growth rates, scaled using two different methods each (see Methods for details). Confidence intervals per scenario are derived on the basis of bootstrap analysis and represent the uncertainty for a typical individual. Allom, allometric. (b) Probability of tumor response of a certain size in melanoma. For each dose level, Monte Carlo simulations were performed taking into account the uncertainty in model parameters, as well as uncertainty in the scaling of the tumor growth/shrinkage. The change from baseline for each simulation replicate was categorized in a manner analogous to RECIST v1.1 (left panel, Q3W; right panel, Q2W).
Figure 3 (a) Simulated tumor response in melanoma (percentage change from baseline diameter) following treatment with pembrolizumab (once every 3 weeks) over 6 months for the six scenarios for melanoma using the fast, medium (MED), and slow growth rates, scaled using two different methods each (see Methods for details). Confidence intervals per scenario are derived on the basis of bootstrap analysis and represent the uncertainty for a typical individual. Allom, allometric. (b) Probability of tumor response of a certain size in melanoma. For each dose level, Monte Carlo simulations were performed taking into account the uncertainty in model parameters, as well as uncertainty in the scaling of the tumor growth/shrinkage. The change from baseline for each simulation replicate was categorized in a manner analogous to RECIST v1.1 (left panel, Q3W; right panel, Q2W).CC BY-NC-ND · PubMed Central
Figure 4 Tornado plot showing the top 16 parameters that have the greatest effect on percentage change from baseline in tumor volume at 26 weeks either with 5× or 0.2× the base parameter value for the 5 mg/kg (left) and 0.5 mg/kg (right) doses. The values plotted are the log (base 10) ratio of the tumor volume at 26 weeks vs. the initial tumor volume, so that negative values represent reduction in tumor volume. For the 0.5‐mg/kg dose, the y axis crosses the x axis at −0.39, which is the log ratio for the baseline parameter values. Similarly, for the 5‐mg/kg dose, the y axis crosses the x axis at −1.29, which is the log ratio for the base parameter values.
Figure 4 Tornado plot showing the top 16 parameters that have the greatest effect on percentage change from baseline in tumor volume at 26 weeks either with 5× or 0.2× the base parameter value for the 5 mg/kg (left) and 0.5 mg/kg (right) doses. The values plotted are the log (base 10) ratio of the tumor volume at 26 weeks vs. the initial tumor volume, so that negative values represent reduction in tumor volume. For the 0.5‐mg/kg dose, the y axis crosses the x axis at −0.39, which is the log ratio for the baseline parameter values. Similarly, for the 5‐mg/kg dose, the y axis crosses the x axis at −1.29, which is the log ratio for the base parameter values.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Chiu, 2013, Exposure-response analysis of the effect of trametinib, a MEK inhibitor, on tumor size in patients with V600 BRAF mutation positive melanoma, J. Pharmacokinet. Pharmacodyn., 40, S115

Cited by

Sorted by citations

See all 120

Related

See all

Metadata

Authors
Lindauer, A., Valiathan, C., Mehta, K., Sriram, V, de Greef, R., Elassaiss-Schaap, J., & de Alwis, D.
Affiliations
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • Merck & Co., Inc.; Rahway New Jersey USA
ORCID
Venue
CPT: Pharmacometrics & Systems Pharmacology
Publisher
Wiley
Published
2016-11-08
Volume
6
Issue
1
Pages
11-20
ISSN
2163-8306 (ISSN-L)
DOI
10.1002/psp4.12130
PMC
PMC5270293
OpenAlex
W2554268745
Cited by
120
References
26
Citations by year
2026: 8 · 2025: 6 · 2024: 18 · 2023: 5 · 2022: 20 · 2021: 11 · 2020: 14 · 2019: 16 · 2018: 11 · 2017: 7 · 2016: 3
FWCI
6.64
Type
journal article
Language
en
Open access
Licence
Locations
  • CPT Pharmacometrics & Systems Pharmacology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Gilead Sciences
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords
pembrolizumab, PD-1 inhibitors, tumor growth inhibition, dose-ranging, receptor occupancy, compartmental pharmacokinetic model, monoclonal antibodies, cancer immunotherapy, dose-response relationship
MeSH terms
Animals, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Humans, Mice, Inbred C57BL, Models, Biological, Tumor Burden, Mice, Rats, Translational Research, Biomedical, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review